A real-world study assessing the safety/tolerability of eslicarbazepine acetate in patients with intellectual disability and psychiatric comorbidities using data form the Euro-Esli study
Latest Information Update: 31 Aug 2020
At a glance
- Drugs Eslicarbazepine acetate (Primary)
- Indications Epilepsy
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2020 New trial record